Cancer, Results, Scientific

AACR roundup: Checkpoint cocktails score early successes as Roche’s triple shows high response rate in frontline triple negative breast cancer

Roche today spelled out its best early-stage case for a new triple therapy combo to tackle triple negative breast cancer — a particularly lethal variety of cancer that has proven tough to treat.

Read on for more: Little TG Therapeutics looks for applause on latest umbralisib data; Add-on from Chi-Med, AstraZeneca helps Tagrisso-resistant lung cancer patients; Astellas spells out positive Xospata PhIII data in AML patients; Preclinical neoantigen study finds 4 promising targets for spurring an immune response


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,800+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->